PCA
GPCR icon

Private Capital Advisors’s Structure Therapeutics GPCR Stock Holding History

Private Capital Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.66M Buy
34,389
+27,041
+368% +$1.85M 0.19% 35
2025
Q4 		$511K Sell
7,348
-47,837
-87% -$1.95M 0.05% 52
2025
Q3 		$1.55M Buy
+55,185
New +$1.1M 0.17% 39

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Private Capital Advisors's GPCR Position: Q1 2026 in Review

Private Capital Advisors increased its Structure Therapeutics (GPCR) stake by 368% in Q1 2026, buying an estimated $1.85M and bringing the position to 34,389 shares worth $1.66M. The position accounts for 0.19% of the portfolio, ranked #35.

Private Capital Advisors first reported a position in GPCR in Q3 2025 and has held it in 3 quarters since. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Private Capital Advisors held 34,389 shares of Structure Therapeutics worth $1.66M as of Q1 2026.
  • Private Capital Advisors bought 27,041 Structure Therapeutics shares in Q1 2026, an estimated $1.85M.
  • Structure Therapeutics made up 0.19% of Private Capital Advisors's portfolio in Q1 2026, its #35 holding.
  • Private Capital Advisors first reported a position in Structure Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Private Capital Advisors's 13F filing for Q1 2026, filed 12 May 2026.